EsoCap AG has announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 10,744,095 on August 18, 2020. The patent is directed at the smart application technology enabling specific site-directed treatment of several diseases of the esophagus.

“Issue of the U.S. patent is a major milestone confirming the novelty of EsoCap's proprietary technology”, commented Isabelle Racamier, EsoCap AG CEO. “Grant of this patent further bolsters EsoCap's intellectual property position.”

Under a worldwide agreement, the University of Greifswald in Germany has granted EsoCap the exclusive rights to this unique drug delivery technology developed by the University of Greifswald.

Up to now, local treatment of diseases of the esophagus was not possible due to conventional drug formulations’ ultra-short transit time. “We look forward to continuing development of EsoCap smart application technology to address the tremendous patient need that exists in at least six esophageal diseases affecting 370 million patients”, said Dr. Peter Stangier, Director Strategic Planning at EsoCap AG.

About EsoCap
EsoCap AG is a Swiss privately funded company based in Basel, Switzerland.

EsoCap's vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through development of a unique and innovative topical drug delivery platform.

Effective topical treatment of the esophagus is extremely difficult to achieve due to the ultra-short drug contact time of one to two seconds from the mouth to the stomach.

EsoCap owns and develops a unique drug delivery platform allowing the efficient topical application of drug substances for the local treatment of diseases of the upper gastrointestinal tract.

For more information, please visit www.esocapbiotech.com.

Contact:
Isabelle Racamier, CEO
EsoCap AG
Malzgasse 9
4052 Basel
Switzerland
isabelle.racamier@esocapbiotech.com